

2031, necessary expenses with respect to the research, development, manufacturing, production, and purchase, at the discretion of the Secretary, of vaccines, therapeutics, ancillary supplies necessary for the administration of such vaccines and therapeutics, and medical devices to prevent, prepare for, and respond to SARS-CoV-2 or any viral variant mutating therefrom with pandemic potential and COVID-19 or other public health threats, of which—

“(1) \$4,000,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research, advanced research, development, manufacturing, and procurement of medical countermeasures, which may include supporting, maintaining, and improving domestic manufacturing surge capacity of medical products or platform technologies for use during a public health emergency, pursuant to section 319L of the Public Health Service Act;

“(2) \$1,500,000,000 shall be for the Strategic National Stockpile pursuant to section 319F-2 of the Public Health Service Act related to the procurement and maintenance of medical products and ancillary medical supplies necessary to respond to public health threats, which may include through the establishment and maintenance of domestic manufacturing surge capacity or vendor managed supply reserves;

“(3) \$2,000,000,000 shall be for the National Institutes of Health to support the research and development of medical countermeasures, including broad-spectrum antivirals for SARS-CoV-2;

“(4) \$1,000,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research and development of broad-spectrum antivirals for SARS-CoV-2; and

“(5) \$1,500,000,000 shall be for the Secretary for rapid screening, identification, and development of compounds and platform technologies that may support preparedness for and response to a potential public health threat.

“SEC. 2304. FUNDING FOR COVID-19 VACCINE, THERAPEUTIC, AND DEVICE ACTIVITIES AT THE FOOD AND DRUG ADMINISTRATION.

“In addition to amounts otherwise available, there is appropriated to the Secretary for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$500,000,000, to remain available until expended, to prevent, prepare for, and respond to COVID-19, domestically or internationally, including the development and review of medical countermeasures to address COVID-19 and emerging variants of COVID-19, and which may be used for the evaluation of the continued performance, safety, and effectiveness, including with respect to emerging COVID-19 variants, of vaccines, therapeutics, and diagnostics approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID-19; facilitation of advanced continuous manufacturing activities related to production of vaccines and related materials; facilitation and conduct of inspections related to the manufacturing of vaccines, therapeutics, and devices delayed or cancelled for reasons related to COVID-19, including modernizing inspection processes; facilitation of the use of real world evidence and real world data for approved, cleared, licensed, or authorized medical products; review of devices authorized for use for the treatment, prevention, or diagnosis of COVID-19; and oversight of the supply chain and mitigation of shortages of vaccines, therapeutics, and devices approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID-19 by the Food and Drug Administration.

“SEC. 2305. REDUCED COST-SHARING.

“(a) IN GENERAL.—Section 1402 of the Patient Protection and Affordable Care Act is amended by redesignating subsection (f) as subsection (g) and by inserting after subsection (e) the following new subsection:

“(f) SPECIAL RULE FOR INDIVIDUALS WHO RECEIVE UNEMPLOYMENT COMPENSATION DURING 2021.—For purposes of this section, in the case of an individual who has received, or has been approved to receive, unemployment compensation for any week beginning during 2021, for the plan year in which such week begins—

“(1) such individual shall be treated as meeting the requirements of subsection (b)(2), and

“(2) for purposes of subsections (c) and (d), there shall not be taken into account any household income of the individual in excess of 133 percent of the poverty line for a family of the size involved.”

“(b) EFFECTIVE DATE.—The amendment made by this section shall apply to plan years beginning after December 31, 2020.

“Subtitle E—Testing

“SEC. 2401. FUNDING FOR COVID-19 TESTING, CONTACT TRACING, AND MITIGATION ACTIVITIES.

“(a) IN GENERAL.—In addition to amounts otherwise available, there is appropriated to the Secretary of Health and Human Services (in this subtitle referred to as the ‘Secretary’) for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$40,080,000,000, to remain available until expended, to”

SA 1299. Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

On page 84, line 9, strike “to be” and all that follows through “COVID-19” on line 19, page 84 and insert the following: to prevent, prepare for, and respond to COVID-19, domestically or internationally, including the development and review of medical countermeasures to address COVID-19 and emerging variants of COVID-19, and which may be used for the evaluation of the continued performance, safety, and effectiveness, including with respect to emerging COVID-19 variants, of vaccines, therapeutics, and diagnostics approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID-19; facilitation of advanced continuous manufacturing activities related to production of vaccines and related materials; facilitation and conduct of inspections related to the manufacturing of vaccines, therapeutics, and devices delayed or cancelled for reasons related to COVID-19, including modernizing inspection processes; facilitation of the use of real world evidence and real world data for approved, cleared, licensed, or authorized medical products.

SA 1300. Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and

Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

Strike section 2501 and insert the following:

SEC. 2501. RESEARCH AND DEVELOPMENT OF MEDICAL COUNTERMEASURES AND ANCILLARY MEDICAL SUPPLIES.

(a) IN GENERAL.—In addition to amounts otherwise available, there is appropriated to the Secretary of Health and Human Services (in this subtitle referred to as the ‘Secretary’) for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$7,660,000,000, to remain available through September 30, 2031, necessary expenses with respect to the research, development, manufacturing, production, and purchase, at the discretion of the Secretary, of vaccines, therapeutics, ancillary supplies necessary for the administration of such vaccines and therapeutics, and medical devices to prevent, prepare for, and respond to SARS-CoV-2, or any viral variant mutating therefrom with pandemic potential and COVID-19, or other public health threats, of which—

(1) \$3,064,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research, advanced research, development, manufacturing, and procurement of medical countermeasures, which may include supporting, maintaining, and improving domestic manufacturing surge capacity of medical products or platform technologies for use during a public health emergency, pursuant to section 319L of the Public Health Service Act (42 U.S.C. 247d-7e);

(2) \$1,149,000,000 shall be for the Strategic National Stockpile pursuant to section 319F-2 of the Public Health Service Act (42 U.S.C. 247d-6b) related to the procurement and maintenance of medical products and ancillary medical supplies necessary to respond to public health threats, which may include through the establishment and maintenance of domestic manufacturing surge capacity or vendor managed supply reserves;

(3) \$1,532,000,000 shall be for the National Institutes of Health to support the research and development of medical countermeasures, including broad-spectrum antivirals for SARS-CoV-2;

(4) \$766,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research and development of broad-spectrum antiviral drugs for SARS-CoV-2; and

(5) \$1,149,000,000 shall be for the Secretary for rapid screening, identification, and development of compounds and platform technologies that may support preparedness for and response to a potential public health threat.

SA 1301. Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

Strike sections 2402 through 2404 of the amendment and insert the following:

SEC. 2402. PUBLIC HEALTH SURVEILLANCE AND INFECTIOUS DISEASE FORECASTING.

In addition to amounts otherwise available, there is appropriated to the Secretary